Breaking News

Novartis Acquires Kate Therapeutics in $1.1B Deal

Adds enabling technology platforms and therapeutic candidates for neuromuscular diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis has acquired Kate Therapeutics, a San Diego-based, preclinical stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat neuromuscular diseases, in a transaction valued at $1.1 billion, comprising an upfront payment and potential additional milestone payments.   Kate Therapeutics’ primary programs include preclinical candidates for Duchenne muscular dystrophy (DMD), facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters